Akili (AKLI) Stock Price, News & Analysis

Company Overview

Akili, Inc., a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. It also offers selective stimulus management engine mechanism to activate the fronto-parietal cortex area in the brain; body brain trainer for attention, impulsivity, working memory, and goal management; and spatial navigation engine for spatial navigation, memory, and planning and organization. The company was founded in 2011 and is headquartered in Boston, Massachusetts.

Key Stats

• Today's Range: $0.43 to $0.43
• 50-Day Range: $0.42 to $0.44
• 52-Week Range: $0.19 to $1.25
• Volume: N/A
• Average Volume: 2.20 million shs
• Market Capitalization: $34.01 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

AKLI Stock Analysis - Frequently Asked Questions

How were Akili's earnings last quarter?

Akili, Inc. (NASDAQ:AKLI) announced its earnings results on Thursday, May, 11th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.18) by $0.04. The business had revenue of $0.11 million for the quarter. Akili had a negative net margin of 2,492.04% and a negative trailing twelve-month return on equity of 79.93%.

What other stocks do shareholders of Akili own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Akili investors own include Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), Tesla (TSLA), Taiwan Semiconductor Manufacturing (TSM), NVIDIA (NVDA), P3 Health Partners (PIII) and uniQure (QURE).

Company Calendar

• Last Earnings: 5/11/2023
• Today: 11/04/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:AKLI
• CUSIP: N/A
• CIK: 1850266
• Web: www.akiliinteractive.com
• Phone: 650-931-6236
• Fax: N/A
• Employees: 130
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.61)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-59,490,000.00
• Net Margins: -2,492.04%
• Pretax Margin: -2,489.32%
• Return on Equity: -79.93%
• Return on Assets: -59.16%

Debt

• Debt-to-Equity Ratio: 0.08
• Current Ratio: 5.80
• Quick Ratio: 5.80

Sales & Book Value

• Annual Sales: $1.95 million
• Price / Sales: 17.46
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.75 per share
• Price / Book: 0.58

Miscellaneous

• Outstanding Shares: 78,727,000
• Free Float: 70,776,000
• Market Cap: $34.01 million
• Optionable: Optionable
• Beta: 1.72